文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

老年大手术术中氯胺酮预防术后谵妄或疼痛:国际多中心双盲随机临床试验

Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.
PubMed 文献 · Lancet · 2017-05-30
一句话结论老年大手术术中单次亚麻醉剂量氯胺酮不降低术后谵妄发生率,且可能因诱发不良体验而造成伤害。

PODCAST研究为国际多中心随机双盲试验,纳入672例60岁以上全身麻醉下行心脏或非心脏大手术的成人,随机分为安慰剂组、氯胺酮0.5 mg/kg组和1.0 mg/kg组,麻醉诱导后切皮前给药。术后前3天每日两次用Confusion Assessment Method评估谵妄。氯胺酮组合并组与安慰剂组谵妄发生率无差异(19.45% vs 19.82%,绝对差0.36%,95%CI -6.07至7.38,p=0.92)。随氯胺酮剂量增加,术后幻觉(p=0.01)和噩梦(p=0.03)增多。作者结论认为单次亚麻醉剂量氯胺酮未减少老年大手术后谵妄,且可能通过诱发负性体验造成伤害。

要点

  • 60岁以上全身麻醉下行心脏或非心脏大手术者,术中单次亚麻醉剂量氯胺酮不降低术后谵妄发生率(19.45% vs 19.82%,p=0.92)。
  • 氯胺酮0.5 mg/kg和1.0 mg/kg组术后幻觉(p=0.01)和噩梦(p=0.03)随剂量增加而增多。
  • 心血管、肾脏、感染、胃肠道及出血等不良事件各组间无显著差异(p=0.69)。
  • 作者结论:单次亚麻醉剂量氯胺酮未减少老年大手术后谵妄,且可能因诱发负性体验造成伤害。

适用人群与场景

  • 60岁以上、全身麻醉下行心脏或非心脏大手术的成人。

诊断标准与关键阈值

  • 术后前3天每日两次使用Confusion Assessment Method评估谵妄。

处置流程与药物剂量

  • 麻醉诱导后、切皮前给予单次氯胺酮0.5 mg/kg或1.0 mg/kg,或安慰剂(生理盐水)。

研究设计与关键结果

  • PODCAST研究为国际多中心随机双盲试验,2014年2月6日至2016年6月26日评估1360例,随机672例:安慰剂组222例、氯胺酮0.5 mg/kg组227例、氯胺酮1.0 mg/kg组223例。
  • 氯胺酮组合并组与安慰剂组谵妄发生率无差异:19.45% vs 19.82%,绝对差0.36%(95%CI -6.07至7.38,p=0.92)。
  • 与安慰剂相比,随氯胺酮剂量增加术后幻觉(p=0.01)和噩梦(p=0.03)增多。
  • 不良事件(心血管、肾脏、感染、胃肠道、出血)单独分析(各p>0.40)或合并分析(安慰剂组36.9%、氯胺酮0.5 mg/kg组39.6%、氯胺酮1.0 mg/kg组40.8%,p=0.69)各组间无显著差异。

证据类型、等级与局限

  • 证据类型:国际多中心、双盲、随机对照试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为单次亚麻醉剂量氯胺酮未减少老年大手术后谵妄,且可能因诱发负性体验造成伤害。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delirium is a common and serious postoperative complication. Subanaesthetic ketamine is often administered intraoperatively for postoperative analgesia, and some evidence suggests that ketamine prevents delirium. The primary purpose of this trial was to assess the effectiveness of ketamine for prevention of postoperative delirium in older adults.

METHODS: The Prevention of Delirium and Complications Associated with Surgical Treatments [PODCAST] study is a multicentre, international randomised trial that enrolled adults older than 60 years undergoing major cardiac and non-cardiac surgery under general anaesthesia. Using a computer-generated randomisation sequence we randomly assigned patients to one of three groups in blocks of 15 to receive placebo (normal saline), low-dose ketamine (0·5 mg/kg), or high dose ketamine (1·0 mg/kg) after induction of anaesthesia, before surgical incision. Participants, clinicians, and investigators were blinded to group assignment. Delirium was assessed twice daily in the first 3 postoperative days using the Confusion Assessment Method. We did analyses by intention-to-treat and assessed adverse events. This trial is registered with clinicaltrials.gov, number NCT01690988.

FINDINGS: Between Feb 6, 2014, and June 26, 2016, 1360 patients were assessed, and 672 were randomly assigned, with 222 in the placebo group, 227 in the 0·5 mg/kg ketamine group, and 223 in the 1·0 mg/kg ketamine group. There was no difference in delirium incidence between patients in the combined ketamine groups and the placebo group (19·45% vs 19·82%, respectively; absolute difference 0·36%, 95% CI -6·07 to 7·38, p=0·92). There were more postoperative hallucinations (p=0·01) and nightmares (p=0·03) with increasing ketamine doses compared with placebo. Adverse events (cardiovascular, renal, infectious, gastrointestinal, and bleeding), whether viewed individually (p value for each >0·40) or collectively (36·9% in placebo, 39·6% in 0·5 mg/kg ketamine, and 40·8% in 1·0 mg/kg ketamine groups, p=0·69), did not differ significantly across groups.

INTERPRETATION: A single subanaesthetic dose of ketamine did not decrease delirium in older adults after major surgery, and might cause harm by inducing negative experiences.

FUNDING: National Institutes of Health and Cancer Center Support.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Avidan MS, Maybrier HR, Abdallah AB, et al. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Lancet. 2017. PMID: 28576285. doi:10.1016/S0140-6736(17)31467-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。